Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development

Rhea-AI Summary

Incannex (Nasdaq: IXHL) reported approximately $75 million in cash and no debt after a recent financing, while market capitalization is about $46 million, producing a negative enterprise value. Proceeds will fund the DReAMzz Phase 2 dose-optimization study for IHL-42X; PSX-001 development continues with an open IND.

The company expects to begin dosing in DReAMzz in the coming months and retains a board-approved share buyback program.

Positive

• $75 million cash position with no debt
• Proceeds fund DReAMzz Phase 2 dose-optimization study for IHL-42X
• IHL-42X holds FDA Fast Track designation
• PSX-001 has an open IND and positive early clinical outcomes
• Participation by healthcare-focused institutional investors in financing

Negative

• Market capitalization ~$46 million, below cash balance, creating a negative enterprise value
• Financing implies share issuance that may affect shareholder base (unspecified dilution)

Key Figures

Cash balance: $75 million Market capitalization: $46 million Clinical programs: 2 programs +5 more

8 metrics

Cash balance $75 million Post-financing cash position highlighted in release

Market capitalization $46 million Company-stated market cap at current trading levels

Clinical programs 2 programs IHL-42X for OSA and PSX-001 for GAD

DReAMzz study phase Phase 2 Crossover dose-optimization study for IHL-42X

Next stage Phase 3 program Planned optimized Phase 3 for IHL-42X after DReAMzz

Fast Track status FDA Fast Track Designation for IHL-42X in obstructive sleep apnea

Share buyback program Remaining capacity Board-approved buyback with capacity still available

Patient population Generalized anxiety disorder PSX-001 targets GAD, described as substantially underserved

Market Reality Check

Price: $3.31 Vol: Volume 344,625 is below t...

low vol

$3.31 Last Close

Volume Volume 344,625 is below the 20-day average of 751,909, suggesting limited pre-news positioning. low

Technical Shares at $3.31 are trading below the 200-day MA of $11.60, reflecting a weak longer-term trend.

Peers on Argus

Peer moves are mixed, with names like RMTI up 9.28% and AYTU, CPIX down, and onl...

1 Down

Peer moves are mixed, with names like RMTI up 9.28% and AYTU, CPIX down, and only one momentum peer (GELS) moving down. This points to stock-specific dynamics rather than a broad sector move.

Historical Context

5 past events · Latest: Mar 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 17	Nasdaq compliance	Positive	+0.0%	Regained compliance with Nasdaq minimum bid price and highlighted cash position.
Mar 12	Equity offering	Negative	-48.4%	Registered direct offering and warrants to raise about $10M in gross proceeds.
Mar 12	Clinical pathway	Positive	-48.4%	Outlined enhanced IHL-42X development plan after statistically significant Phase 2 data.
Feb 25	Reverse split	Neutral	-42.1%	Implemented 1-for-30 reverse stock split to support Nasdaq bid-price compliance.
Feb 18	Analyst coverage	Positive	+8.3%	Coverage update citing strong Phase 2 OSA data and $68.9M cash balance.

Pattern Detected

Recent history shows large negative reactions to financing and structural actions, while positive clinical and coverage news has produced more mixed or muted price responses.

Recent Company History

Over the past month, Incannex has combined capital raises, a reverse split, and clinical updates. A 1-for-30 reverse split and a registered direct offering around $10M coincided with sharp declines of about -42% to -48% the next day. In contrast, positive IHL-42X Phase 2 data, Nasdaq bid-price compliance, and updated coverage citing $68.9M–$75M cash and no debt saw either modest gains or flat trading. Today’s balance-sheet highlight reinforces that cash-rich profile despite prior adverse reactions to financing steps.

Market Pulse Summary

This announcement underscores Incannex’s balance-sheet strength, with about $75 million in cash, no ...

Analysis

This announcement underscores Incannex’s balance-sheet strength, with about $75 million in cash, no debt, and two advancing clinical programs, IHL-42X and PSX-001. It reiterates plans to fund the DReAMzz Phase 2 study while reserving capital for an optimized Phase 3 path. Recent history includes a reverse split and a registered direct offering, so investors may watch cash usage, upcoming dosing in DReAMzz, and progress under FDA Fast Track as key markers of execution risk.

Key Terms

phase 2, phase 3, fast track designation, obstructive sleep apnea, +3 more

7 terms

phase 2 medical

"complete DReAMzz Phase 2 study while preserving capital"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

phase 3 medical

"preserve the majority of its existing capital for the next stage of development, including an optimized Phase 3 program"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

fast track designation regulatory

"supported by FDA Fast Track designation"

A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.

obstructive sleep apnea medical

"advances IHL-42X for obstructive sleep apnea (OSA)"

Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.

generalized anxiety disorder medical

"PSX-001 for the treatment of generalized anxiety disorder (GAD)"

Generalized anxiety disorder is a chronic mental health condition marked by persistent, excessive worry about everyday things that is hard to control and interferes with daily life. Think of it like a smoke alarm that stays on for weeks or months, making work, decision-making and productivity harder; for investors it matters because it drives demand for treatments, affects workforce performance and can influence regulatory scrutiny, clinical trial design and healthcare spending.

clinical advisory board medical

"Establishment of a Clinical Advisory Board comprised of leading experts"

A clinical advisory board is a group of independent medical and scientific experts a company consults to guide clinical development, trial design, regulatory strategy and product use. Like a navigation team advising a ship’s captain, they bring real‑world experience and credibility that can speed development, reduce regulatory and clinical risk, and influence investor confidence by signaling that the science and path to market are being thoughtfully managed.

contract research organization medical

"Appointment of a leading contract research organization and recruitment of clinical sites"

A contract research organization (CRO) is an outside company hired to run medical and scientific work for drug, device or biotech developers—like an experienced project manager and lab team that companies rent instead of building in-house. Investors care because CROs influence development speed, quality and cost: delays or successes in trials affect client spending, regulatory risk and ultimately revenues for both the sponsor and the CRO.

AI-generated analysis. Not financial advice.

Company well-funded to complete DReAMzz Phase 2 study while preserving capital for optimized Phase 3 program

MELBOURNE, Australia and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today reported that it holds approximately $75 million in cash with no debt, following the completion of its recently announced financing led by dedicated healthcare-focused institutional investors.

At current trading levels, Incannex’s market capitalization is approximately $46 million — representing a significant disconnect to the Company’s $75 million cash position and resulting in a negative enterprise value. Management believes this disconnect does not reflect the Company’s financial strength or, the continued advancement of its clinical pipeline, or the external validation demonstrated by the participation of healthcare-focused institutional investors in the recently completed financing.

The participation of healthcare-focused institutional investors in this financing reflects meaningful external validation of both the Company’s clinical program and the long-term value potential of IHL-42X. Incannex now holds approximately $75 million in cash with no debt, positioning the Company with a strong balance sheet as it advances IHL-42X for obstructive sleep apnea (OSA) and PSX-001 for the treatment of generalized anxiety disorder (GAD).

Capital Position Supports Near- and Long-Term Development

Proceeds from the recently completed financing are expected to fund the Company’s DReAMzz Phase 2 crossover dose-optimization study for IHL-42X. The study is designed to further optimize the ratio of the two active pharmaceutical ingredients within the drug candidate, with the goal of maximizing efficacy across both objective physiological endpoints and patient-reported outcomes.

Funding DReAMzz with proceeds from the recent financing allows the Company to preserve the majority of its existing capital for the next stage of development, including an optimized Phase 3 program.

The Company’s board-approved share buyback program remains available and carries remaining capacity, providing management with an additional tool to deliver shareholder value when market conditions warrant.

Continued Progress Advancing IHL-42X

Over the past year, Incannex has made substantial progress advancing the clinical development of IHL-42X, including:

• Successful Phase 2 clinical results demonstrating statistically significant improvements in obstructive sleep apnea outcomes
• Advancement into the DReAMzz Phase 2 crossover dose-optimization study, designed to further enhance efficacy ahead of Phase 3 and supported by FDA Fast Track designation
• Establishment of a Clinical Advisory Board comprised of leading experts in the obstructive sleep apnea field, providing guidance on clinical strategy and study design
• Appointment of a leading contract research organization and recruitment of clinical sites
• A clearly defined pathway toward an optimized Phase 3 development program
  

While the positive Phase 2 results could have supported direct progression into Phase 3, the Company elected to undertake the DReAMzz study to further refine dosing and maximize the probability of success in late-stage development. Management believes this approach reduces execution risk, improves the probability of Phase 3 success, and represents the most capital-efficient route to a registrational outcome — with the potential to shorten the overall pathway to registration by optimizing the program ahead of Phase 3. Importantly, the Company expects to begin dosing patients in the DReAMzz study within the coming months — a near-term milestone that reflects continued forward momentum in the program.

Progress Advancing PSX-001 for Generalized Anxiety Disorder

In addition to IHL-42X, Incannex continues to advance PSX-001, the Company’s oral synthetic psilocybin therapy for the treatment of generalized anxiety disorder (GAD).

PSX-001 has generated positive clinical outcomes supporting the therapeutic potential of the program. The Company has established a leading clinical advisory board comprised of experts in psychiatry and psychedelic-assisted therapies, providing strategic guidance on clinical development and study design. With an open IND with the FDA and a clear pathway to upcoming milestones, management believes PSX-001 represents a high-value second clinical asset within the Incannex pipeline, targeting a large and substantially underserved patient population.

“Following the completion of this financing, Incannex is in a strong financial position — approximately $75 million in cash, no debt, and well-funded through our DReAMzz study and into an optimized Phase 3 program,” said Joel Latham, President and Chief Executive Officer of Incannex Healthcare. “This disciplined capital strategy allows us to advance IHL-42X from a position of financial strength while maintaining a robust balance sheet as we progress toward late-stage development and potential registration. The healthcare-focused institutional investors who participated in this financing share our conviction in the long-term value proposition of the program, and their participation reflects meaningful external validation of both the science and the strategy.”

Mr. Latham added, “At current levels, we are trading at a meaningful disconnect to our cash balance alone — before attributing any value to two advancing clinical programs, FDA Fast Track designation, or the contributions of our clinical advisory boards. We believe that disconnect is unsustainable, and that continued execution will correct it.”

Positioned for Value Creation

With $75 million in cash, no debt, two advancing clinical programs, and a clear development pathway for both IHL-42X and PSX-001, Incannex is moving forward from a position of financial and operational strength. Management believes the Company’s current valuation presents a compelling opportunity, and remains focused on executing its development strategy to drive recognition of the underlying value of its programs.

About Incannex Healthcare Inc. 

Incannex is leading the way in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. The Company is advancing three clinical-stage product candidates based on evidence-based innovation and supported by streamlined operations. Incannex's lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnea. In a Phase 2 development program, IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. Approved for Phase 2 clinical development, PSX-001 is an oral synthetic psilocybin treatment for the treatment of generalized anxiety disorder. Incannex's programs target disorders that have limited, inadequate, or no approved pharmaceutical treatment options. For additional information on Incannex, please visit our website at www.incannex.com.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the anticipated use of proceeds from the offering, the sufficiency of these proceeds to fund the DReAMzz Phase 2 study for IHL-42X, whether the Company’s current cash on hand will remain available to fund Phase 3 development and expectations regarding its use, the potential value of the Company’s drug candidates and business, including these values as compared to available cash, opportunities, the strategy, timing and future development of the Company’s drug candidates, including the anticipated timing for a Phase 3 clinical trial, the potential value of the Company’s drug candidates and results Phase 2 crossover dose trial, future use of the buyback program. When or if used in this communication, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company, its operations or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the risk that the offering may not close, the risk that the Company’s estimates and current projections regarding the sufficiency of the proceeds of the offering and its current cash on hand to fund the Company’s planned operations may be incorrect and the Company may use these resources faster than anticipated, the risk that the common warrants may not be exercised or may not be exercised in cash, and other risks described in the section entitled "Risk Factors" described in the prospectus supplement and in the Company's annual report on Form 10-K for the fiscal year ended June 30, 2025, filed with the SEC on September 29, 2025, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, which can be obtained on the SEC website at www.sec.gov and are made available on the Company’s website upon their filing with the SEC. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

Investor & Media Contacts
CORE IR
(212) 655-0924
investors@incannex.com  
media@incannex.com.au 

FAQ

How much cash does Incannex (IXHL) have after the March 18, 2026 financing?

Incannex holds approximately $75 million in cash with no debt. According to the company, this balance follows a financing led by healthcare-focused institutional investors and is intended to fund near-term development activities including DReAMzz Phase 2.

What will Incannex (IXHL) use the financing proceeds for and when will dosing start?

Proceeds will fund the DReAMzz Phase 2 crossover dose-optimization study for IHL-42X. According to the company, dosing is expected to begin within the coming months to refine dosing ahead of an optimized Phase 3 program.

Why does Incannex (IXHL) have a negative enterprise value despite $75M cash?

Market capitalization is reported at approximately $46 million, below the company's cash balance, producing a negative enterprise value. According to the company, this gap reflects a disconnect the company believes will correct with continued execution.

What regulatory and clinical milestones does Incannex (IXHL) cite for IHL-42X?

IHL-42X has demonstrated positive Phase 2 results and holds FDA Fast Track designation. According to the company, the DReAMzz study aims to optimize dosing to improve Phase 3 success probability and shorten the pathway to registration.

What is the status of PSX-001 development at Incannex (IXHL)?

PSX-001 is an oral synthetic psilocybin therapy with positive clinical outcomes and an open IND. According to the company, PSX-001 remains an advancing second clinical asset targeting generalized anxiety disorder with advisory board support.

Does Incannex (IXHL) have measures for shareholder value after the financing?

Yes; the company maintains a board-approved share buyback program with remaining capacity. According to the company, management may use the program when market conditions warrant to deliver shareholder value.